Detecting bladder cancer early using a new urine test.
Official title: A Multiplex Protein Biomarker-Based Immunoassay for the Early Detection of Bladder Cancer and its Implications in Tumor Biology
Funded at Cedars-Sinai Medical Center · NIH-11042277 · Data updated 2026-11-12
This study is working on a new urine test to help find bladder cancer early, especially for people who are at higher risk, so they can get treated sooner and improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | April 7, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $416,215 |
| NIH project number | 5R01CA277810-03 |
| Project ID | NIH-11042277 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for bladder cancer, particularly those exposed to certain carcinogens.
✕Less likely to help
Patients who do not have risk factors for bladder cancer or those already diagnosed with advanced stages of the disease may not benefit from this research.
What this research studies
This research focuses on developing a new urine test that can detect bladder cancer at an early stage, which is crucial for improving survival rates. The approach involves identifying a specific set of biomarkers associated with bladder cancer and creating a multiplex immunoassay to analyze these biomarkers in urine samples. By testing individuals who are at high risk for bladder cancer, the researchers aim to provide a reliable screening method that can lead to earlier diagnosis and better treatment outcomes.
Why it matters
Potential benefit: If successful, this research could significantly improve early detection of bladder cancer, leading to higher survival rates for patients.
How similar studies have gone: Previous research has shown promising results with similar biomarker-based approaches for cancer detection, indicating potential for success in this area.
Where this research is happening
-
Cedars-Sinai Medical Center
Los Angeles, United States Active
Researchers
- Principal investigator: Rosser, Charles J — Cedars-Sinai Medical Center
- Study coordinator: Rosser, Charles J
Related research
Other NIH-funded projects on the same topics.
-
Population modeling to reduce bladder cancer burden
Aimed at predicting and guiding effective, population-based ways to prevent and control bladder cancer.
-
Blocking a new immune checkpoint in bladder cancer
Researchers are trying medicines that block a newly found immune pathway to help people with bladder cancer, especially those whose tumors do not respond to current immunotherapy.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Understanding why bladder cancer spreads and resists treatment
This grant studies how advanced bladder cancer changes and spreads across the body, aiming to uncover why it’s hard to treat.
-
Molecular clues to bladder cancer cell changes and therapy response
This NIH grant looks at how bladder cancer cells change their identity and how that affects response to treatment, with a focus on aggressive neuroendocrine variants.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.